Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lymphoblastic Leukemia, Adult
- Acute Lymphoblastic Leukemia, Pediatric
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 3 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03676504
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Prof. Dr. Michael Schmitt University Hospital Heidelberg, Department V Principal Investigator: Prof. Dr. Andreas Kulozik University Hospital Heidelberg, University Medical Center for Children and Adolescents
Get Well Soon